Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
7.8
5.6
Journals
IJMS
Special Issues
Biomarkers of Treatment Response in Psychiatric Disorders
ijms-logo
Submit to IJMS Review for IJMS Propose a Special Issue

Journal Menu

► Journal Menu

Journal Browser

► Journal Browser
share announcement

Biomarkers of Treatment Response in Psychiatric Disorders

A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Neurobiology".

Deadline for manuscript submissions: closed (30 November 2021) | Viewed by 7759

Special Issue Editor

Dr. Cynthia Marie-Claire

E-Mail Website
Guest Editor
French National Institute of Health and Medical Research (Inserm), Paris, France
Interests: bipolar disorder; biomarkers; relapse; treatment response; cocaine; addiction; epigenetics; transcriptomics

Special Issue Information

Dear Colleagues,

Psychiatric disorders are leading causes of chronic disability and are characterized by high clinical variability, high levels of relapses/recurrences, and unpredictable treatment response. In the context of the development of personalized medicine in psychiatry, it is important to improve patients’ stratification but also to monitor response and compliance. For this purpose, deciphering the molecular mechanisms underlying treatment response in psychiatric disorders is essential.

We are pleased to invite you to contribute to this Special Issue of the International Journal of Molecular Sciences. It will focus on recent research concerning the molecular mechanisms involved in treatment response and potential of biomarkers to predict treatment response in psychiatric disorders.

High-quality manuscripts presenting original research or expert review articles on both human subjects and preclinical models will be considered. Research areas may include (but are not limited to) the following: genetic, epigenetic, and transcriptomic biomarkers.

I look forward to receiving your contributions.

Dr. Cynthia Marie-Claire
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • Psychiatric disorders
  • Biomarkers
  • Treatment response
  • Neuropsychopharmacology
  • Genetics
  • Epigenetics
  • Transcriptomics
  • Molecular psychiatry

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Review

28 pages, 1126 KiB  
Review
COMT Val/Met and Psychopathic Traits in Children and Adolescents: A Systematic Review and New Evidence of a Developmental Trajectory toward Psychopathy
by Tuana Kant, Emiko Koyama, Clement C. Zai, Joseph H. Beitchman and James L. Kennedy
Int. J. Mol. Sci. 2022, 23(3), 1782; https://0-doi-org.brum.beds.ac.uk/10.3390/ijms23031782 - 04 Feb 2022
Cited by 3 | Viewed by 4011
Abstract
Psychopathic traits in youth may lead to adult criminal behaviors/psychopathy. The Val158Met polymorphism of catechol-O-methyltransferase (COMT) may influence the risk for psychopathy-related behaviors, while acting as a biomarker for predicting treatment response to dopaminergic medications. The literature shows inconsistent findings, making [...] Read more.
Psychopathic traits in youth may lead to adult criminal behaviors/psychopathy. The Val158Met polymorphism of catechol-O-methyltransferase (COMT) may influence the risk for psychopathy-related behaviors, while acting as a biomarker for predicting treatment response to dopaminergic medications. The literature shows inconsistent findings, making the interpretation of COMT’s role difficult. The aims of this article are (i) to conduct a systematic review to analyze the effects of COMT Val158Met on psychopathic traits in children and adolescents, and (ii) to present new evidence on the developmental trajectory of the association of Val158Met and youth psychopathic traits. For the systematic review, a literature search was conducted using PubMed, EMBASE, OVID Medline and PsychINFO with the search terms for psychopathic traits, Val158Met and age of interest. In our genotype study, the COMT Val158Met genotype of 293 youth with European ancestry was analyzed in association with the psychopathy-related behavior scores from the Child Behavior Checklist and the Psychopathy Screening Device. To examine the potential influence of developmental changes, the sample was split into at or above and below age 13, and analyses were performed in males and females separately. The literature search yielded twenty-eight articles to be included in the systematic review, which demonstrated mixed results on the association depending on environmental factors, sex ratios, age groups and behavioral disorder diagnoses. The results from our genotype study revealed that Met homozygous youth in the below age 13 group and conversely Val carrier youth in the above age 13 group were more likely to display psychopathic traits. To our knowledge, this is the first study to systematically review the effects of COMT Val158Met on psychopathic traits in childhood and adolescence, and to provide new evidence on the changing effects of Val158Met on psychopathy-related behaviors with development. Elucidating the role of the COMT genotype in conjunction with the child versus adolescent stage of development for psychopathic traits may help predict treatment response, and may lead to early intervention and prevention strategies. Full article
(This article belongs to the Special Issue Biomarkers of Treatment Response in Psychiatric Disorders)
►▼ Show Figures

Figure 1

23 pages, 359 KiB  
Review
Genetic and Epigenetic Markers of Lithium Response
by Claudia Pisanu, Anna Meloni, Giovanni Severino and Alessio Squassina
Int. J. Mol. Sci. 2022, 23(3), 1555; https://0-doi-org.brum.beds.ac.uk/10.3390/ijms23031555 - 29 Jan 2022
Cited by 6 | Viewed by 3274
Abstract
The mood stabilizer lithium represents a cornerstone in the long term treatment of bipolar disorder (BD), although with substantial interindividual variability in clinical response. This variability appears to be modulated by genetics, which has been significantly investigated in the last two decades with [...] Read more.
The mood stabilizer lithium represents a cornerstone in the long term treatment of bipolar disorder (BD), although with substantial interindividual variability in clinical response. This variability appears to be modulated by genetics, which has been significantly investigated in the last two decades with some promising findings. In addition, recently, the interest in the role of epigenetics has grown significantly, since the exploration of these mechanisms might allow the elucidation of the gene–environment interactions and explanation of missing heritability. In this article, we provide an overview of the most relevant findings regarding the pharmacogenomics and pharmacoepigenomics of lithium response in BD. We describe the most replicated findings among candidate gene studies, results from genome-wide association studies (GWAS) as well as post-GWAS approaches supporting an association between high genetic load for schizophrenia, major depressive disorder or attention deficit/hyperactivity disorder and poor lithium response. Next, we describe results from studies investigating epigenetic mechanisms, such as changes in methylation or noncoding RNA levels, which play a relevant role as regulators of gene expression. Finally, we discuss challenges related to the search for the molecular determinants of lithium response and potential future research directions to pave the path towards a biomarker guided approach in lithium treatment. Full article
(This article belongs to the Special Issue Biomarkers of Treatment Response in Psychiatric Disorders)
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop